Citigroup’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,912
| Closed | -$3K | – | 6577 |
|
|
2021
Q2 | $3K | Hold |
1,912
| – | – | ﹤0.01% | 5954 |
|
|
2021
Q1 | $4K | Hold |
1,912
| – | – | ﹤0.01% | 5983 |
|
|
2020
Q4 | $4K | Hold |
1,912
| – | – | ﹤0.01% | 7172 |
|
|
2020
Q3 | $5K | Hold |
1,912
| – | – | ﹤0.01% | 7079 |
|
|
2020
Q2 | $8K | Hold |
1,912
| – | – | ﹤0.01% | 7159 |
|
|
2020
Q1 | $1K | Hold |
1,912
| – | – | ﹤0.01% | 7563 |
|
|
2019
Q4 | $2K | Hold |
1,912
| – | – | ﹤0.01% | 7581 |
|
|
2019
Q3 | $1K | Sell |
1,912
-127
| -6% | -$78 | ﹤0.01% | 7663 |
|
|
2019
Q2 | $1K | Sell |
2,039
-1
| -0% | -$2 | ﹤0.01% | 7714 |
|
|
2019
Q1 | $6K | Hold |
2,040
| – | – | ﹤0.01% | 7403 |
|
|
2018
Q4 | $4K | Hold |
2,040
| – | – | ﹤0.01% | 7432 |
|
|
2018
Q3 | $9K | Hold |
2,040
| – | – | ﹤0.01% | 7397 |
|
|
2018
Q2 | $9K | Hold |
2,040
| – | – | ﹤0.01% | 7239 |
|
|
2018
Q1 | $15K | Buy |
2,040
+1,990
| +3,980% | +$14.9K | ﹤0.01% | 6896 |
|
|
2017
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 7726 |
|
|
2017
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 7576 |
|
|
2017
Q2 | $1K | Hold |
50
| – | – | ﹤0.01% | 7282 |
|
|
2017
Q1 | $1K | Hold |
50
| – | – | ﹤0.01% | 7143 |
|
|
2016
Q4 | $1K | Hold |
50
| – | – | ﹤0.01% | 7148 |
|
|
2016
Q3 | $1K | Hold |
50
| – | – | ﹤0.01% | 7013 |
|
|
2016
Q2 | $1K | Sell |
50
-6,378
| -99% | -$125K | ﹤0.01% | 7017 |
|
|
2016
Q1 | $122K | Buy |
6,428
+4,107
| +177% | +$79K | ﹤0.01% | 5520 |
|
|
2015
Q4 | $61K | Buy |
2,321
+2,000
| +623% | +$69.5K | ﹤0.01% | 5775 |
|
|
2015
Q3 | $14K | Buy |
321
+7
| +2% | +$264 | ﹤0.01% | 6274 |
|
|
2015
Q2 | $10K | Sell |
314
-147
| -32% | -$4.27K | ﹤0.01% | 6485 |
|
|
2015
Q1 | $15K | Sell |
461
-1,888
| -80% | -$63.9K | ﹤0.01% | 6260 |
|
|
2014
Q4 | $89K | Buy |
2,349
+1,697
| +260% | +$46.7K | ﹤0.01% | 5328 |
|
|
2014
Q3 | $18K | Sell |
652
-107
| -14% | -$2.83K | ﹤0.01% | 5973 |
|
|
2014
Q2 | $22K | Sell |
759
-1,049
| -58% | -$33.9K | ﹤0.01% | 5768 |
|
|
2014
Q1 | $67K | Sell |
1,808
-2,192
| -55% | -$83.1K | ﹤0.01% | 5297 |
|
|
2013
Q4 | $166K | Buy |
4,000
+2,884
| +258% | +$113K | ﹤0.01% | 4823 |
|
|
2013
Q3 | $60K | Sell |
1,116
-294
| -21% | -$17.1K | ﹤0.01% | 5149 |
|
|
2013
Q2 | $75K | Buy |
+1,410
| New | +$70.4K | ﹤0.01% | 5089 |
|
Other funds holding NAVB
BCM
ACM
Citigroup's NAVB Position: Q3 2021 in Review
Citigroup sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2021, closing a stake of 1,912 shares — an estimated $3K sold.
Citigroup first reported a position in NAVB in Q2 2013 and held it in 33 quarters. The position peaked at $166K in Q4 2013. 29 funds tracked by Wall St. Rank hold NAVB as of Q3 2021.
- Citigroup reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2021 after selling out during the quarter.
- Citigroup sold 1,912 Navidea Biopharmaceuticals Inc. shares in Q3 2021, an estimated $3K.
- Citigroup first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 33 quarters.
- Citigroup's Navidea Biopharmaceuticals Inc. position peaked at $166K in Q4 2013.
- 29 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2021.
Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.